Each day, NIT Research can produce more Actinium-225 than the rest of the world combined.

About Nano Imrad Technology (NIT)

NIT is a medical research and development company. Our products include diagnostic imaging and therapeutic medical isotopes. Our core technology is immune labeled radionuclide nanoparticles.

We are offering Actinium-225 in millicurie quantities, beginning in the second quarter of 2023.

Theranostic immunolabled radiopharmaceuticals for prostate and breast cancer will be ready for Phase I Clinical trials third quarter of 2023 pending Health Canada, FDA, MHRA (Medicines and Healthcare products Regulatory Agency-UK), and Israel (Ministry of Health (MOH) Pharmaceutical Administration) approvals. Theranostic radiopharmaceuticals are in our pipline for colon, and lung cancers.


Actinium is a radioactive metal that is used in the field of cancer treatment, specifically as an aid in radiation therapy. It is a naturally occurring element, found in uranium ore, and can be produced synthetically in a laboratory environment. Learn More about Actinium-225


Find out more about NIT and Actinium-225